This HTML5 document contains 50 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n10http://linked.opendata.cz/resource/drugbank/drug/DB02772/identifier/pubchem-compound/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
foafhttp://xmlns.com/foaf/0.1/
n16http://linked.opendata.cz/resource/drugbank/drug/DB02772/identifier/kegg-drug/
n11http://linked.opendata.cz/resource/drugbank/drug/DB02772/identifier/pubchem-substance/
n17http://linked.opendata.cz/resource/drugbank/drug/DB02772/identifier/drugbank/
n20http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n4http://www.rxlist.com/cgi/generic/
n8http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n14http://linked.opendata.cz/resource/drugbank/drug/DB02772/identifier/chebi/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n5http://linked.opendata.cz/ontology/drugbank/
n6http://linked.opendata.cz/resource/drugbank/property/
n13http://linked.opendata.cz/resource/drugbank/drug/DB02772/identifier/pharmgkb/
n18http://linked.opendata.cz/resource/drugbank/drug/DB02772/identifier/wikipedia/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/resource/drugbank/drug/DB02772/identifier/pdb/
n15http://linked.opendata.cz/resource/drugbank/drug/DB02772/identifier/kegg-compound/

Statements

Subject Item
n2:DB02772
rdf:type
n5:Drug
n5:description
A nonreducing disaccharide composed of glucose and fructose linked via their anomeric carbons. It is obtained commercially from sugarcane, sugar beet (beta vulgaris), and other plants and used extensively as a food and a sweetener. [PubChem]
n5:generalReferences
# Ten S, Maclaren N: Insulin resistance syndrome in children. J Clin Endocrinol Metab. 2004 Jun;89(6):2526-39. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15181020 # Aguilera AA, Diaz GH, Barcelata ML, Guerrero OA, Ros RM: Effects of fish oil on hypertension, plasma lipids, and tumor necrosis factor-alpha in rats with sucrose-induced metabolic syndrome. J Nutr Biochem. 2004 Jun;15(6):350-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15157941 # Fukuchi S, Hamaguchi K, Seike M, Himeno K, Sakata T, Yoshimatsu H: Role of fatty acid composition in the development of metabolic disorders in sucrose-induced obese rats. Exp Biol Med (Maywood). 2004 Jun;229(6):486-93. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15169967 # Lombardo YB, Drago S, Chicco A, Fainstein-Day P, Gutman R, Gagliardino JJ, Gomez Dumm CL: Long-term administration of a sucrose-rich diet to normal rats: relationship between metabolic and hormonal profiles and morphological changes in the endocrine pancreas. Metabolism. 1996 Dec;45(12):1527-32. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8969287
n5:group
experimental
owl:sameAs
n8:DB02772 n20:DB02772
dcterms:title
Sucrose
adms:identifier
n10:46936484 n11:46506134 n12:SUC n13:PA451525 n14:17992 n15:C00089 n16:D00025 n17:DB02772 n18:Sucrose
n5:synthesisReference
Francois B. Paul, Pierre F. Monsan, Magali M. C. Remaud, Vincent P. Pelenc, "Process for the enzymatic preparation from sucrose of a mixture of sugars having a high content of isomaltose, and products obtained." U.S. Patent US4861381, issued April, 1956.
foaf:page
n4:venofer.htm
n5:IUPAC-Name
n6:271B56EA-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B56F0-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B56EF-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B56EC-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B56ED-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B56EE-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B56E8-363D-11E5-9242-09173F13E4C5 n6:271B5700-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B5702-363D-11E5-9242-09173F13E4C5 n6:271B56E9-363D-11E5-9242-09173F13E4C5 n6:271B56E6-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B56E7-363D-11E5-9242-09173F13E4C5
n5:pKa
n6:271B5704-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Acceptor-Count
n6:271B56F6-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B56F7-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B56F1-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B56F2-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B56F4-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B56F3-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B56F5-363D-11E5-9242-09173F13E4C5
n5:caco2-Permeability
n6:271B5703-363D-11E5-9242-09173F13E4C5
n5:casRegistryNumber
57-50-1
n5:Bioavailability
n6:271B56FC-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B56FE-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B56FF-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n6:271B5701-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B56FB-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B56FA-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B56FD-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B56EB-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B56F8-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B56F9-363D-11E5-9242-09173F13E4C5